45,000 Dogs, One Question: What Actually Makes Dogs Live Longer?
The Dog Aging Project (DAP) has enrolled over 45,000 companion dogs across the United States — not laboratory animals, but real pets in real households — collecting detailed health, lifestyle, environmental, and genetic data at a scale no canine study has ever attempted.
That distinction matters. Laboratory studies control variables but study dogs in artificial environments. DAP studies aging as it actually occurs: in the diverse, messy, uncontrolled conditions where companion dogs live. Creevy et al. (2022) published the foundational framework in Nature, establishing DAP as an open-science initiative with publicly available datasets accessible to researchers worldwide.
For background on the project’s original design and early findings, see Dog Aging Project: key findings.
TRIAD Rapamycin Trial: What We Know So Far
The Test of Rapamycin In Aging Dogs (TRIAD) is a double-blinded, placebo-controlled trial enrolling 580 middle-aged, large and giant breed dogs to determine whether low-dose rapamycin extends healthy lifespan. It is the largest veterinary clinical trial ever conducted and the first rigorous test of a pharmacological longevity intervention in companion dogs.
Trial Design
TRIAD dogs are 7+ years old, weigh 40+ pounds, and are otherwise healthy. They receive either low-dose rapamycin or placebo for three years, with quarterly veterinary assessments, annual comprehensive exams, periodic bloodwork, and owner-reported quality-of-life surveys.
The primary endpoint is a composite of survival and major disease events (cancer diagnosis, organ failure, loss of mobility). Secondary endpoints include cognitive function, cardiac function, body composition, and biomarker trajectories including DNA methylation age (see epigenetic clocks in dogs).
Interim Data (2025)
The DAP consortium released initial safety and compliance data in 2025. Full efficacy results are not yet available — the trial’s primary endpoints require the full 3-year observation period. But the interim data revealed several important signals:
- Compliance rates exceeded 90% — owners successfully administered medication and attended study visits at very high rates, validating the companion dog model for longevity drug trials.
- Serious adverse events were comparable between rapamycin and placebo groups in the initial observation period, supporting the safety profile of the low-dose regimen used.
- Cardiac function data from echocardiographic sub-studies showed trends toward preserved systolic function in the rapamycin group, consistent with earlier pilot studies (see rapamycin in dogs).
Full results are expected in 2027-2028. If rapamycin extends healthy lifespan in this large, well-controlled trial, it would be the strongest evidence ever generated for pharmacological lifespan extension in a large mammal.
Social Determinants of Canine Health
McCoy et al. (2023) used DAP data to investigate something unprecedented in veterinary science: the relationship between owner socioeconomic factors and dog health outcomes. Drawing parallels to the well-established social determinants of health in human medicine, they found:
- Dogs in households with higher income had better health outcomes, more frequent veterinary visits, and longer projected lifespans.
- Neighborhood factors — walkability, access to green space, air quality — correlated with dog activity levels and health markers.
- Owner education level was associated with differences in preventive care utilization.
These findings do not imply that wealthier owners care more about their dogs. They highlight that access to veterinary care, quality nutrition, and safe exercise environments is unevenly distributed — and that canine health disparities mirror human health disparities in striking ways.
Cognitive Aging: The Largest Canine Cognition Dataset
Yarborough et al. (2022) analyzed cognitive function data from thousands of DAP dogs using the Canine Social and Learned Behavior (CSLB) questionnaire. Key findings:
- Cognitive decline begins earlier than most owners recognize. Subtle changes in learning, memory, and social interaction are detectable in dogs as young as 7-8 years in large breeds.
- Dogs with more social interaction (with other dogs and with people outside the household) showed slower cognitive decline trajectories.
- Physical activity was independently associated with better cognitive scores at all ages.
- Cognitive decline acceleration was steeper after clinical signs first appeared, supporting the value of early detection. See canine cognitive decline early action plan.
Environmental and Lifestyle Findings
DAP’s environmental exposure data has revealed several associations that, while preliminary, are generating research hypotheses:
Secondhand smoke exposure. Dogs in smoking households showed higher rates of respiratory conditions and inflammatory markers. See pollution exposure and canine health.
Altitude and lifespan. Preliminary data suggests dogs living at higher altitudes may have slightly different aging trajectories, consistent with human epidemiological data on altitude and longevity.
Diet diversity. Dogs fed more varied diets (multiple protein sources, fresh food components) showed different health marker profiles than dogs fed single-formula kibble diets, though causation cannot be determined from observational data.
Exercise regularity. Consistent daily exercise was more strongly associated with health outcomes than total exercise volume, suggesting regularity matters more than intensity. See exercise protocols by breed size.
Precision Medicine for Dogs
The DAP dataset is enabling the development of breed-specific and individual risk prediction models. By combining genetic data with phenotypic and environmental information from tens of thousands of dogs, researchers are building tools to:
- Predict breed-specific disease risk with greater precision than breed-average statistics.
- Identify genetic variants associated with exceptional longevity.
- Develop individualized prevention protocols based on a dog’s genetic profile, environment, and lifestyle.
This represents a shift from population-level veterinary guidelines to precision medicine — tailoring prevention and treatment recommendations to the individual dog. See genetic testing for dogs for current clinical applications.
What Owners Can Do
The DAP findings reinforce several evidence-based longevity strategies:
- Maintain regular physical activity. Consistency matters more than intensity. Daily walks and play sessions support both physical and cognitive health.
- Prioritize social engagement. Regular interaction with other dogs and varied human contact supports cognitive maintenance.
- Pursue preventive veterinary care. Annual comprehensive exams with appropriate screening catch problems early. See senior dog screening protocol.
- Monitor cognitive changes early. Use structured assessment tools to detect subtle cognitive decline before it becomes advanced. See canine cognitive decline early action plan.
- Consider enrolling in DAP. The project continues to enroll dogs. Participating provides your dog with additional health monitoring while contributing to the largest canine aging study ever conducted. Visit dogagingproject.org for enrollment information.
Limitations
DAP is an observational study (except for the TRIAD trial), meaning it identifies associations but cannot prove causation. Owner-reported data is subject to recall bias and inconsistency.
The enrolled population may not represent the general dog population — owners who enroll in research studies tend to be more health-conscious and have greater resources. Environmental exposure data relies on proxy measures (ZIP code-level air quality, neighborhood walkability scores) rather than individual-level measurements. TRIAD results are not yet available for the primary endpoint.
Frequently Asked Questions
What is the Dog Aging Project and why does it matter?
The Dog Aging Project is the largest canine aging study ever conducted, with over 45,000 companion dogs enrolled. Run by the University of Washington, it tracks genetics, environment, lifestyle, and health outcomes across the canine lifespan. Its findings directly inform evidence-based longevity strategies for dog owners and contribute to translational aging research that benefits both dogs and humans.
What has the TRIAD rapamycin trial found so far?
The TRIAD study is testing rapamycin in 580 dogs to determine whether the drug extends healthy lifespan. While full results are not yet published, preliminary data contributed to the study’s continuation, suggesting measurable biological effects. The trial’s completion will provide the most rigorous evidence to date on pharmaceutical lifespan extension in companion animals.
What lifestyle factors has the Dog Aging Project linked to longer lifespan?
Key findings include that dogs with more social engagement show fewer signs of cognitive decline, dogs living in households with higher socioeconomic resources tend to have better health outcomes (likely reflecting access to veterinary care and nutrition), and environmental factors including neighborhood walkability correlate with activity levels and health metrics.
Can I enroll my dog in the Dog Aging Project?
Yes. The Dog Aging Project accepts new participants through its website. Dogs of any age, breed, and health status can enroll in the observational study. Enrollment involves annual owner surveys and optional veterinary record sharing. A smaller subset of dogs is selected for biological sample collection and deeper analysis.
Bottom Line
The Dog Aging Project has produced the largest canine aging dataset in history and is running the most rigorous test of a longevity drug ever conducted in companion dogs. Key findings to date include the importance of social engagement for cognitive health, socioeconomic parallels between human and canine health disparities, and preliminary safety data from the TRIAD rapamycin trial. Full TRIAD efficacy results are expected in 2027-2028. For owners, DAP reinforces the value of consistent exercise, social enrichment, preventive veterinary care, and early cognitive monitoring — strategies that are actionable now while pharmacological interventions continue to be evaluated.